Prestige BioPharma  "Creating Differences and Value for Human Health "        

Development Pipelines

PBP's current biosimilar portfolio includes HD201 (Herceptin Biosimilar), HD204 (Avastin Biosimilar), and PBP1502 (Humira Biosimilar), advanced clinical to nonclinical development stages. Based on the technology and capabilities established from the successful development of these biosimilars, the next tier of biosimilars as well as biobetter and new antibody therapeutics are under development in conjunction with reputable discovery institutions and academia.